4,4-Difluoropiperidine → HCID 59605383, compound

HRID 1923028Notes

Reaction equation

HRID 1923028 reaction equation
Br[CH2:2][C:3]1[N:4]([CH3:28])[C:5]2[C:10]([N:11]=1)=[C:9]([N:12]1[CH2:17][CH2:16][O:15][CH2:14][CH2:13]1)[N:8]=[C:7]([N:18]1[C:22]3[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=3[N:20]=[C:19]1[CH3:27])[N:6]=2.[F:29][C:30]1([F:36])[CH2:35][CH2:34][NH:33][CH2:32][CH2:31]1>>[F:29][C:30]1([F:36])[CH2:35][CH2:34][N:33]([CH2:2][C:3]2[N:4]([CH3:28])[C:5]3[C:10]([N:11]=2)=[C:9]([N:12]2[CH2:17][CH2:16][O:15][CH2:14][CH2:13]2)[N:8]=[C:7]([N:18]2[C:22]4[CH:23]=[CH:24][CH:25]=[CH:26][C:21]=4[N:20]=[C:19]2[CH3:27])[N:6]=3)[CH2:32][CH2:31]1

Participants

3

Reactant 2

HCID 27583524,4-DifluoropiperidineHCID 596058124-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine

Product 1

HCID 59605383HCID 59605383, compound

Procedure

4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with 4,4-difluoropiperidine via General Procedure E to give 19.3 mg of 278 following reverse phase purification. MS (Q1) 483.2 (M)+

Workup

  1. customto give
  2. custom19.3 mg of 278 following reverse phase purification

Sources & evidence

ORD record
ord-421d10feb4c2476d921b679845bb3d97
Source dataset
uspto-grants-2012_05
Patent number
US08173650B2

Reaction notes

Loading…